Ficolin-2, Human, ELISA kit
Ficolins are a group of proteins containing both a collagen-like domain and a fibrinogen-like domain. Three forms of ficolins have been identified in humans: Ficolin-1 (M-ficolin), Ficolin-2 (L-ficolin),and Ficolin-3 (H-ficolin). Ficolin-2 is produced primarily by the liver. Whereas Ficolin-3 is produced by the liver and the lung and Ficolin-1 by monocytes, leukocytes and lung cells. Ficolin-2 recognizes distinct danger-associated molecular patterns (DAMPs) like GlcNAc-structures in Lipoteichoic Acid (LTA) and fungal 1,3-β-D-glucan. Ficolin-2 also recognizes N-acetylated compounds such as acetylcholine.
Furthermore, Ficolin-2 recognizes apoptotic cells and participates in the removal of host cells. Ficolin-2 circulates in complex with MASP-2 and can activate the lectin complement pathway. Ficolin-2 serum levels are reported with varying concentrations. Polymorphisms in the promoter of the FCN2 gene from which Ficolin-2 is derived are associated with variation in Ficolin-2 serum levels. These polymorphisms may influence the affinity of Ficolin-2 to GlcNAc-structures.
Ficolin-2 deficiencies have not been reported, but low Ficolin-2 serum levels have been associated with recurrent respiratory infections in children. Interestingly, Ficolin-2 has been implicated in the unique immune challenge during pregnancy. In maternal plasma of normal pregnancies, a 4- to 5-fold increase in Ficolin-2 was detected compared to healthy non-pregnant persons. However, significantly lower Ficolin-2 maternal plasma concentrations were associated with pre-eclamptic pregnancies. Therefore, assessment of Ficolin-2 is warranted to study its regulatory role in the innate immune system. Normal human plasma contains a Ficolin-2 concentration ranging from 1 to 14 µg/ml.
You may also like…
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA